The Medical Letter on Drugs and Therapeutics
Tavaborole Topical Solution (Kerydin) for Onychomycosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved tavaborole 5% solution (Kerydin – Anacor Pharmaceuticals) for topical treatment of toenail onychomycosis due to Trichophyton rubrum or Trichophyton mentagrophytes. It is the first oxaborole antifungal drug to be approved for this indication.

STANDARD TREATMENT — Toenail onychomycosis is most often caused by the dermatophytes T. rubrum and T. mentagrophytes, and rarely by nondermatophyte molds and yeasts. Oral terbinafine and oral itraconazole are the drugs of choice for treatment of dermatophyte toenail onychomycosis, but even with prolonged treatment (3 months), cure rates are low and relapse rates are high. Drug interactions and adverse effects, including gastrointestinal symptoms, serious skin reactions, and severe hepatic toxicity are common.1,2 Terbinafine is generally preferred over ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Tavaborole Topical Solution (Kerydin) for Onychomycosis
Article code: 1463d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian